Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06605378 · ClinicalTrials.gov registry record
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
A clinical trial of Chronic Granulomatous Disease (CGD), sponsored by Ensoma.
- Recruiting
- Registry status
- 60
- Enrollment target
- 20
- Study locations
NCT06605378: Recruiting study of Chronic Granulomatous Disease (CGD), sponsored by Ensoma.
NCT06605378 is a study of Chronic Granulomatous Disease (CGD) that is actively recruiting participants, run by Ensoma. The registered enrollment target is 60 participants. The trial reports 20 study locations across 19 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06605378, a study of Chronic Granulomatous Disease (CGD), is actively recruiting participants, sponsored by Ensoma.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Primary Outcome
Level of total adenoviral-specific antibody in blood
Conditions Studied
Study Locations (20)
California
- Home-based telemedicine - Sacramento
- University of California, San Francisco - San Francisco
Alabama
- Home-based telemedicine - Montgomery
Arizona
- Home-based telemedicine - Phoenix
Arkansas
- Home-based telemedicine - Little Rock
Colorado
- Home-based telemedicine - Denver
Connecticut
- Home-based telemedicine - Hartford
Delaware
- Home-based telemedicine - Dover
District of Columbia
- Home-based telemedicine - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2026-06 |
What NCT06605378 shows while recruiting
NCT06605378 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 1 condition, with Chronic Granulomatous Disease (CGD) appearing as the primary indexed condition, and to 0 interventions.
NCT06605378 names 20 study sites across 19 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06605378 about?
NCT06605378 is a clinical study titled "Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease". This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
What is the current status of trial NCT06605378?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2024-11-18. Estimated completion is 2026-06.
What conditions does trial NCT06605378 study?
This clinical trial studies the following conditions: Chronic Granulomatous Disease (CGD).
Who is sponsoring clinical trial NCT06605378?
This trial is sponsored by Ensoma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06605378 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Granulomatous Disease (CGD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI